ABSTRACT As a consequence of their sizes, many loss-of-function genetic mutations fall within large genes. A major gene-therapy tool that could be used to solve large swaths of the genetic diseases that result from these inherited mutations is large-fragment knock-in. I.e. instead of attempting to create separate treatments for each and every location that these mutations occur in, large groups of patients could be aided via a single safe-harbor integration of the full-length coding sequence. Towards this goal, we have created a set of early stage gene-editing enzymes that can help mediate large cargo integration at a safe harbor locus in human cells. When expressed in stable lines, our S-SELeCT ( S ite- S pecific L arg e C argo T argeting) integrase fusions can facilitate integration of a 10 kb plasmid at frequencies up to 32%, and when delivered transiently via plasmid transfection, we were able to achieve up to 13% knock-in. These are the first serine integrase enzymes that have been evolved fully in human cells, and the first to recognize an endogenous symmetric non-pseudosite – the first true human serine integrase attachment site. GRAPHICAL ABSTRACT
Building similarity graph...
Analyzing shared references across papers
Loading...
Alfonso Farruggio
Applied StemCell (United States)
Lin Jiang
Applied StemCell (United States)
Karen Duong
Applied StemCell (United States)
Applied StemCell (United States)
Building similarity graph...
Analyzing shared references across papers
Loading...
Farruggio et al. (Sun,) studied this question.
synapsesocial.com/papers/69a76567badf0bb9e87d8fd7 — DOI: https://doi.org/10.64898/2026.01.30.702954